6-Apr-2026
New study finds interferon therapy to be well-tolerated in compensated hepatitis B cirrhosis
Chinese Medical Journals Publishing House Co., Ltd.Peer-Reviewed Publication
Antivirals given for chronic hepatitis B include nucleos(t)ide analog monotherapy and pegylated interferon-alpha therapy, but the safety of interferon in patients with cirrhosis has been unclear. A study in Portal Hypertension and Cirrhosis analyzed data from two large Chinese cohorts, including 920 patients with compensated cirrhosis, and found that interferon therapy was not associated with a higher risk of serious complications, supporting its use with appropriate monitoring.
- Journal
- Portal Hypertension & Cirrhosis
- Funder
- National Natural Science Foundation of China, Shanghai Municipal Health Commission, Tianjin Health Research Project, Tianjin Key Medical Discipline (Specialty) Construction Project, Major Science and Technology Projects for Liver Disease Research Fund of Ningbo, Research Personnel Cultivation Program of Zhongda Hospital Southeast University, High-level Personnel Project Funding of Jiangsu Province, Zhongda Hospital Affiliated to Southeast University Jiangsu Province High-Level Hospital Pairing Assistance Construction Funds, Fundings for Clinical Trials from Zhongda Hospital School of Medicine Southeast University, China Association of Chinese Medicine Joint Research Initiative on Priority Diseases, Key Research and Development Program of Jiangsu Province, Fundamental Research Fund of Southeast University, Special Medical Experts of Jiangsu Province, Natural Science Foundation of Jiangsu Province